sbrt in combination with ipilimumab/nivolumab in mrcc
Published 4 years ago • 112 plays • Length 4:46Download video MP4
Download video MP3
Similar videos
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
7:03
ipilimumab/nivolumab for favorable-risk mrcc
-
7:36
mrcc patient selection for ipilimumab/nivolumab
-
3:16
optimizing the use of ipilimumab/nivolumab in mrcc
-
2:00
nivolumab and ipilimumab in mrcc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
7:49
immunotherapeutic combinations for mrcc: immotion-151
-
2:08
nivolumab with ipilimumab for mrcc
-
3:19
radvax: nivolumab / ipilimumab with sbrt for metastatic renal cell carcinoma
-
1:03
dr. long on nivolumab/ipilimumab in patients with melanoma brain metastases
-
1:16
dr. mcgregor on combination therapies with nivolumab, cabozantinib, and sunitinib in rcc
-
1:08
dr. motzer on nivolumab/ipilimumab activity in rcc
-
1:34
fda approval of frontline nivolumab/ipilimumab combo in rcc
-
3:45
combination immunotherapy in newly diagnosed mrcc
-
0:51
dr. pal on the frontline approval of nivolumab and ipilimumab in mrcc
-
3:07
checkmate-214: nivolumab/ipilimumab for mrcc?
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc
-
1:55
investigating responses to nivolumab and ipilimumab in advanced rcc
-
9:09
nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced rcc